Johnson & Johnson $JNJ Stock Holdings Lifted by BXM Wealth LLC

BXM Wealth LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 1,361.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 72,240 shares of the company’s stock after buying an additional 67,298 shares during the period. Johnson & Johnson makes up approximately 1.5% of BXM Wealth LLC’s holdings, making the stock its 21st biggest position. BXM Wealth LLC’s holdings in Johnson & Johnson were worth $14,950,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Brighton Jones LLC raised its holdings in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares in the last quarter. United Bank grew its stake in shares of Johnson & Johnson by 110.7% in the 1st quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after purchasing an additional 4,876 shares during the period. Sivia Capital Partners LLC boosted its holdings in shares of Johnson & Johnson by 13.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after acquiring an additional 692 shares in the last quarter. Wealth Group Ltd. boosted its holdings in shares of Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after acquiring an additional 168 shares in the last quarter. Finally, Schnieders Capital Management LLC. lifted its holdings in Johnson & Johnson by 9.8% during the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock worth $11,255,000 after buying an additional 6,584 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $241.01 on Thursday. The company’s 50 day simple moving average is $240.79 and its 200 day simple moving average is $214.35. The stock has a market capitalization of $580.51 billion, a price-to-earnings ratio of 21.81, a price-to-earnings-growth ratio of 2.41 and a beta of 0.34. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $251.71.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The firm had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. As a group, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 1,322 shares of the business’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Barclays increased their price target on Johnson & Johnson from $217.00 to $234.00 and gave the company an “equal weight” rating in a research note on Thursday, March 19th. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. Citigroup increased their target price on Johnson & Johnson from $274.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday. TD Cowen began coverage on Johnson & Johnson in a report on Wednesday. They issued a “buy” rating and a $250.00 price objective for the company. Finally, Leerink Partners raised their price objective on Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $237.57.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Big analyst bullishness — Citigroup raised its price target to $285 and maintained a Buy, signaling a material upside to consensus; Guggenheim and TD Cowen also have Buy calls and lifted targets, supporting near-term demand. Citigroup raises price target to $285
• Positive Sentiment: New/maintained buy coverage from TD Cowen and supportive analyst commentary highlight J&J’s diversified pipeline and attractive risk/reward into earnings. TD Cowen / TipRanks coverage
• Positive Sentiment: Regulatory / product catalyst — J&J launched its next‑gen Varipulse Pro PFA catheter in Europe (CE mark), which could support device revenue growth in electrophysiology. Varipulse Pro launch in Europe
• Positive Sentiment: Specialty therapy wins — permanent U.S. reimbursement code for bladder cancer therapy INLEXZO and distribution deals (e.g., SIRTURO in Japan) reduce commercialization risk and boost revenue visibility in niche franchises. Johnson & Johnson updates key specialty therapies
• Neutral Sentiment: Media/analyst pieces are bullish ahead of Q1 — Barron’s and other outlets recommend buying into the earnings run-up, which supports momentum but also raises expectations risk. Barron’s: Buy ahead of earnings
• Neutral Sentiment: Mixed market commentary — coverage noting the stock “increases yet falls behind the market” and inclusion on low‑volatility/blue‑chip lists boost interest but are not direct fundamental drivers. Zacks: Increases yet falls behind market

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.